Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

@article{Goulis1999RandomisedCT,
  title={Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis},
  author={J. Goulis and G. Leandro and A. Burroughs},
  journal={The Lancet},
  year={1999},
  volume={354},
  pages={1053-1060}
}
BACKGROUND Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease progression and survival is uncertain. The aim of this study was to clarify the efficacy of UDCA in primary biliary cirrhosis. METHODS A systematic review, including the use of meta-analysis, was done for the randomised and switch-over phases of trials comparing UDCA with placebo, obtained from Medline and Embase databases, and from manual searches derived from review… Expand
Urso—panacea or placebo?
BACKGROUND Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease progression is uncertain. The aim of this study was to clarify theExpand
Long-Term Effects of Mid-Dose Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Meta-analysis of Randomized Controlled Trials
TLDR
Long-term treatment with mid-dose UDCA can improve liver biochemistry and survival free of liver transplantation in patients with PBC, and can delay the histological progression in the early-stage patients. Expand
Ursodeoxycholic Acid for Patients With Primary Biliary Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Using Bayesian Approach as Sensitivity Analyses
TLDR
This updated systematic review did not demonstrate any benefit of UDCA on mortality and mortality or liver transplantation in patients with PBC, and meta-regression analyses suggested that UDCA effects seem to be associated with patient's disease severity and trial duration. Expand
Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial
TLDR
UDCA was not found to have any demonstrable effect on the long-term outcome of PBC and did not improve the survival of patients with primary biliary cirrhosis. Expand
Ursodeoxycholic acid for primary biliary cirrhosis.
TLDR
The random-effects model meta-regression showed that the risk of bias of the trials, disease severity of patients at entry, ursodeoxycholic acid dosage, and trial duration were not significantly associated with the intervention effects on all-cause mortality, or on all thecause mortality or liver transplantation. Expand
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future.
TLDR
Results of the clinical trial of Pares et al. are timely because increasing experimental evidence supports the use of UDCA in cholestatic diseases and two meta-analyses suggested that UDCA did not do better than a placebo. Expand
A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten‐year results
TLDR
Neither colchcine plus UDCA nor methotrexateplus UDCA improved survival beyond that predicted by the Mayo prognostic model, however, clinical, histologic, and biochemical improvement observed among those who remained in the study for 10 years suggests a possible benefit of these drugs in a subset of patients. Expand
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
TLDR
High-dose UDCA may be of clinical benefit in PSC, but trials with a larger number of participants and of longer duration are required to establish whether the effect of high- dose UDCA on liver biochemistry, histology, and cholangiography in patients with PSC is translated into improved long-term survival. Expand
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis
TLDR
UDCA appears to be of most benefit when instituted in early stage disease, and although a substantial percentage of patients will achieve biochemical normalization on UDCA alone, there is a continued need for therapeutic options for others who have less complete biochemical responses. Expand
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis
TLDR
UDCA appears to be of most benefit when instituted in early stage disease, and although a substantial percentage of patients will achieve biochemical normalization on UDCA alone, there is a continued need for therapeutic options for others who have less complete biochemical responses. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.
TLDR
Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo, and long-term UDCA therapy improves survival free of Liver transplantation in patients with moderate or severe disease. Expand
Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
TLDR
MA confirmed a beneficial effect of UDCA in PBC on liver tests, histology, and treatment failure, and in CH, there was an improvement in liver Tests, but the evidence for histologic effect was sparse and insignificant. Expand
Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial
TLDR
Although UDCA treatment did not significantly affect time to death or liver transplantation and to clinical complications, the effects on both cholestasis and liver histology suggest that UDCA is safe and may be useful for preventing the progression of primary biliary cirrhosis. Expand
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
TLDR
Ursodiol is a safe and effective treatment for primary biliary cirrhosis and follow-up analysis of 95 liver-biopsy specimens showed a significant improvement in the mean histologic score and in all the characteristic histologic features except fibrosis only in the group given ursodiol. Expand
Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
TLDR
UDCA improved serum enzyme values but not survival, symptoms, serum bilirubin levels, or liver histology, and there was no significant difference in response between initially symptomatic and asymptomatic patients. Expand
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
TLDR
Long-term ursodiol therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation. Expand
Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC.
The administration of ursodeoxycholic acid, a hydrophilic bile acid not hepatotoxic to humans, has been suggested for treatment of primary biliary cirrhosis to improve cholestasis and reduceExpand
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.
TLDR
UDCA was extraordinarily safe and well tolerated, and its use was associated with delayed progression of the disease as defined in this study, however, the lack of effects on symptoms, histology, and the need for liver transplantation or survival indicate that further evaluation is necessary. Expand
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.
TLDR
UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis. Expand
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
TLDR
In conclusion, long‐term UDCA therapy appeared to delay the development of cirrhosis in PBC. Expand
...
1
2
3
4
...